Organisation paid for research Program year 2025 Source: CMS Open Payments

Covance Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$30,746,497

130 payments

Through program year 2025, Covance Clinical Research is reported as receiving $30,746,497 in research payments, across 130 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $3,781,991 20
2024 Research $7,832,247 25
2023 Research $8,223,883 28
2022 Research $1,761,600 10
2021 Research $1,583,403 12
2020 Research $1,757,453 24
2019 Research $5,805,920 11

Breakdown

Who paid Research payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $11,309,425 35 payments
  2. Incyte Corporation $8,154,512 45 payments
  3. Biogen, Inc. $5,292,833 14 payments
  4. Celgene Corporation $3,593,860 17 payments
  5. Mirati Therapeutics, Inc. $1,831,734 5 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $467,550 12 payments
  7. Daiichi Sankyo Inc. $96,583 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 1, Double-Blind, Sponsor-Unblinded, Randomized, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCA034460 When Administered as an Intravenous Infusion to Healthy Adult Participants $2,709,768 8 payments
  2. A Phase 1, Open-label, Crossover Study to Evaluate the Bioequivalence of Intramuscular BIIB017 (Peginterferon Beta-1a) and Subcutaneous BIIB017 in Healthy Volunteers $2,562,847 2 payments
  3. A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants $1,816,475 4 payments
  4. A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Healthy Adult Participants $1,610,594 3 payments
  5. Drug Interaction #1 (CC-92480-CP-XXX2) CYP3A $1,507,630 2 payments
  6. A Study to Evaluate the Drug Levels of BMS-986166 in Healthy Male Participants $1,270,957 3 payments
  7. A Phase 1, Open-label, Two-Part Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants $1,123,923 1 payment
  8. A Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]BMS-986419 in Healthy Male Participants $1,000,274 2 payments
  9. A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on Adagrasib $987,345 2 payments
  10. An Open-Label Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants $964,600 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record